MedTrace Logo

Effect of Sitagliptin on Polycystic Ovarian Syndrome Patients

NCT05972928 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-08-02

No results posted yet for this study

Summary

The Study aims to determine the proposed positive influence of Sitagliptin in manipulating hormonal , metabolic and inflammatory parameters in the treatment of Polycystic ovary syndrome and subsequent infertility

Conditions

  • Polycystic Ovary Syndrome

Interventions

DRUG

Sitagliptin 100mg

Sitagliptin at a dose of 100 mg every 24 hours for 3 months

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-30
Primary Completion
2023-10-30
Completion
2023-10-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05972928 on ClinicalTrials.gov